Charles River Laboratories International (CRL) Financials

$150.62 -8.50 (-5.34%)

Closing price 03:59 PM Eastern

Extended Trading

$150.78 +0.16 (+0.11%)

As of 05:46 PM Eastern

Annual Income Statements for Charles River Laboratories International

This table shows Charles River Laboratories International's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/26/2015	12/31/2016	12/30/2017	12/29/2018	12/28/2019	12/26/2020	12/25/2021	12/31/2022	12/30/2023	12/28/2024	12/27/2025
Net Income / (Loss) Attributable to Common Shareholders	149	155	123	226	252	364	391	486	475	22	-144
Consolidated Net Income / (Loss)	151	156	125	229	254	365	399	493	480	25	-142
Net Income / (Loss) Continuing Operations	152	156	126	227	254	365	399	493	480	25	-142
Total Pre-Tax Income	195	223	297	282	304	447	481	623	581	93	-100
Total Operating Income	206	238	288	331	351	433	590	651	617	227	25
Total Gross Profit	531	644	701	840	958	1,074	1,335	1,463	1,503	1,332	1,323
Total Revenue	1,363	1,681	1,858	2,266	2,621	2,924	3,540	3,976	4,129	4,050	4,015
Operating Revenue	1,363	1,681	1,858	2,266	2,621	2,924	3,540	3,976	4,129	4,050	4,015
Total Cost of Revenue	832	1,037	1,157	1,426	1,663	1,850	2,206	2,513	2,627	2,718	2,692
Operating Cost of Revenue	832	1,037	1,157	1,426	1,663	1,850	2,206	2,513	2,627	2,718	2,692
Total Operating Expenses	325	406	413	509	607	641	745	812	885	1,104	1,298
Selling, General & Admin Expense	300	365	371	444	518	529	620	665	748	751	743
Amortization Expense	24	42	41	65	90	112	125	147	137	138	179
Impairment Charge	-	-	-	-	-	-	-	0.00	0.00	215	376
Total Other Income / (Expense), net	-11	-15	8.67	-50	-47	14	-109	-28	-36	-134	-125
Interest Expense	15	28	30	64	61	86	74	59	137	126	107
Interest & Investment Income	1.04	1.31	0.69	0.81	1.52	0.83	0.65	0.78	5.20	8.58	4.94
Other Income / (Expense), net	3.01	12	38	13	12	100	-36	31	96	-17	-23
Income Tax Expense	43	67	171	54	50	82	82	130	101	68	43
Preferred Stock Dividends Declared	-	-	-	-	-	-	-	0.00	0.00	12	0.00
Net Income / (Loss) Attributable to Noncontrolling Interest	1.77	1.60	2.09	2.35	2.04	1.00	7.86	6.38	5.75	3.09	2.18
Basic Earnings per Share	$3.21	$3.29	$2.60	$4.72	$5.17	$7.35	$7.77	$9.57	$9.27	$0.20	($2.91)
Weighted Average Basic Shares Outstanding	46.50M	47.01M	47.48M	47.95M	48.73M	49.55M	50.29M	50.81M	51.23M	51.38M	49.56M
Diluted Earnings per Share	$3.13	$3.23	$2.54	$4.62	$5.07	$7.20	$7.60	$9.48	$9.22	$0.20	($2.91)
Weighted Average Diluted Shares Outstanding	46.50M	47.96M	48.56M	49.02M	49.69M	50.61M	51.43M	51.30M	51.45M	51.63M	49.56M
Weighted Average Basic & Diluted Shares Outstanding	46.50M	47.01M	47.40M	48M	48.96M	49.78M	50.49M	50.99M	51.35M	51.14M	49.23M

This table shows Charles River Laboratories International's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/30/2023	3/30/2024	6/29/2024	9/28/2024	12/28/2024	3/29/2025	6/28/2025	9/27/2025	12/27/2025	3/28/2026
Net Income / (Loss) Attributable to Common Shareholders	87	187	73	94	70	-214	25	52	54	-277	-15
Consolidated Net Income / (Loss)	88	189	74	94	70	-214	26	53	56	-276	-15
Net Income / (Loss) Continuing Operations	88	189	74	94	70	-214	26	53	56	-276	-15
Total Pre-Tax Income	113	209	99	120	91	-217	36	71	87	-294	-30
Total Operating Income	152	133	126	152	117	-168	75	100	134	-283	120
Total Gross Profit	362	364	345	354	349	284	318	357	339	310	295
Total Revenue	1,027	1,013	1,012	1,026	1,010	1,003	984	1,032	1,005	994	996
Operating Revenue	1,027	1,013	1,012	1,026	1,010	1,003	984	1,032	1,005	994	996
Total Cost of Revenue	665	649	667	672	661	718	666	675	666	685	701
Operating Cost of Revenue	665	649	667	672	661	718	666	675	666	685	701
Total Operating Expenses	210	231	219	202	232	452	243	257	205	593	175
Selling, General & Admin Expense	176	197	186	170	199	196	178	192	178	196	159
Amortization Expense	34	34	33	32	32	41	65	65	27	21	15
Total Other Income / (Expense), net	-39	76	-27	-32	-26	-49	-39	-29	-47	-11	-150
Interest Expense	34	34	35	33	30	28	28	30	25	24	27
Interest & Investment Income	1.37	1.59	2.20	3.01	1.53	1.84	1.40	1.10	1.42	1.02	1.03
Other Income / (Expense), net	-6.26	108	5.83	-2.24	2.59	-23	-12	0.15	-23	12	-124
Income Tax Expense	25	20	25	25	21	-3.04	10	19	32	-18	-15
Net Income / (Loss) Attributable to Noncontrolling Interest	0.63	1.87	1.52	0.18	0.64	-8.27	0.41	0.37	1.13	0.27	0.04
Basic Earnings per Share	$1.70	$3.66	$1.31	$1.75	$1.34	($4.20)	$0.50	$1.06	$1.11	($5.58)	($0.30)
Weighted Average Basic Shares Outstanding	51.28M	51.23M	51.44M	51.55M	51.39M	51.38M	50.68M	49.15M	49.21M	49.56M	48.95M
Diluted Earnings per Share	$1.69	$3.63	$1.30	$1.74	$1.33	($4.17)	$0.50	$1.06	$1.10	($5.57)	($0.30)
Weighted Average Diluted Shares Outstanding	51.61M	51.45M	51.84M	51.85M	51.58M	51.63M	50.85M	49.32M	49.43M	49.56M	48.95M
Weighted Average Basic & Diluted Shares Outstanding	51.30M	51.35M	51.51M	51.63M	51.14M	51.14M	49.12M	49.21M	49.22M	49.23M	48.17M

This table details how cash moves in and out of Charles River Laboratories International's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/26/2015	12/31/2016	12/30/2017	12/29/2018	12/28/2019	12/26/2020	12/25/2021	12/31/2022	12/30/2023	12/28/2024	12/27/2025
Net Change in Cash & Equivalents	-30	2.93	35	40	43	-6.93	13	-5.10	43	-79	10
Net Cash From Operating Activities	307	317	318	441	481	547	761	620	684	735	738
Net Cash From Continuing Operating Activities	307	317	318	441	481	547	761	620	684	735	738
Net Income / (Loss) Continuing Operations	152	156	126	227	254	365	399	493	480	25	-142
Consolidated Net Income / (Loss)	151	156	125	229	254	365	399	493	480	25	-142
Depreciation Expense	95	127	131	162	198	235	266	304	314	362	403
Non-Cash Adjustments To Reconcile Net Income	29	60	19	75	34	-18	129	42	27	452	552
Changes in Operating Assets and Liabilities, net	31	-26	43	-23	-4.82	-36	-32	-219	-138	-104	-76
Net Cash From Investing Activities	-328	-693	-73	-955	-682	-602	-1,438	-608	-563	-245	-209
Net Cash From Continuing Investing Activities	-328	-693	-73	-955	-682	-602	-1,438	-608	-563	-245	-209
Purchase of Property, Plant & Equipment	-63	-55	-82	-140	-141	-167	-229	-325	-319	-233	-219
Acquisitions	-248	-648	-25	-825	-516	-419	-1,293	-283	-195	-5.48	0.00
Purchase of Investments	-34	-40	-46	-25	-22	-27	-46	-158	-54	-53	-20
Divestitures	0.00	0.00	72	-	0.00	0.00	123	163	0.00	0.00	17
Sale and/or Maturity of Investments	20	48	9.13	36	0.94	11	6.53	4.55	6.67	42	9.10
Other Investing Activities, net	-2.22	3.69	-0.52	-0.81	-3.89	-1.07	0.26	-9.35	-2.29	4.55	3.36
Net Cash From Financing Activities	-7.26	381	-208	558	232	47	673	-42	-86	-551	-537
Net Cash From Continuing Financing Activities	-7.26	381	-208	558	232	47	673	-42	-86	-551	-537
Repayment of Debt	-422	-675	-377	-2,221	-3,143	-2,206	-6,281	-2,940	-856	-1,525	-1,363
Repurchase of Common Equity	-117	-12	-107	-14	-18	-24	-41	-39	-24	-119	-361
Issuance of Debt	493	1,045	237	2,755	3,358	2,231	6,951	2,952	776	1,082	1,228
Other Financing Activities, net	39	23	39	38	35	47	43	-16	18	12	-40
Effect of Exchange Rate Changes	-	-	-	-	11	0.79	18	26	8.04	-17	19

This table details how cash moves in and out of Charles River Laboratories International's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/30/2023	3/30/2024	6/29/2024	9/28/2024	12/28/2024	3/29/2025	6/28/2025	9/27/2025	12/27/2025	3/28/2026
Net Change in Cash & Equivalents	-43	119	54	-158	31	-6.07	26	-47	24	6.78	-18
Net Cash From Operating Activities	205	221	130	194	252	159	172	205	214	148	41
Net Cash From Continuing Operating Activities	205	221	130	194	252	159	172	205	214	148	41
Net Income / (Loss) Continuing Operations	88	189	74	94	70	-214	26	53	56	-276	-15
Consolidated Net Income / (Loss)	88	189	74	94	70	-214	26	53	56	-276	-15
Depreciation Expense	79	81	85	86	88	102	120	120	85	78	67
Non-Cash Adjustments To Reconcile Net Income	44	-58	25	38	42	347	52	35	51	414	124
Changes in Operating Assets and Liabilities, net	-5.37	9.77	-55	-25	52	-76	-27	-2.22	22	-69	-135
Net Cash From Investing Activities	-80	-238	-86	-62	-21	-76	-45	-37	-34	-93	-408
Net Cash From Continuing Investing Activities	-80	-238	-86	-62	-21	-76	-45	-37	-34	-93	-408
Purchase of Property, Plant & Equipment	-66	-78	-79	-39	-39	-76	-59	-35	-36	-89	-56
Acquisitions	-	-145	-	-5.48	-	-	0.00	-	-	-	-405
Purchase of Investments	-14	-18	-14	-22	-9.73	-7.61	-5.30	-2.79	-4.45	-7.53	-8.49
Divestitures	-	-	0.00	-	-	-	17	-	-	-	60
Sale and/or Maturity of Investments	1.01	2.71	7.50	4.86	27	2.22	1.60	0.50	3.53	3.47	2.92
Other Investing Activities, net	-0.99	-0.25	-0.28	-0.09	0.01	4.91	0.10	0.24	2.81	0.21	-1.46
Net Cash From Financing Activities	-163	124	18	-286	-208	-76	-105	-227	-153	-52	348
Net Cash From Continuing Financing Activities	-163	124	18	-286	-208	-76	-105	-227	-153	-52	348
Repayment of Debt	-218	-321	-295	-706	-343	-181	-149	-745	-260	-209	-358
Repurchase of Common Equity	-0.04	-0.14	-9.35	-8.91	-101	-0.12	-353	-7.35	-0.09	-0.10	-208
Issuance of Debt	51	443	301	440	236	105	416	547	107	157	912
Other Financing Activities, net	3.94	1.16	22	-11	0.78	0.77	-19	-22	0.00	0.71	1.22
Effect of Exchange Rate Changes	-6.19	13	-8.39	-3.34	7.70	-13	5.27	13	-3.03	3.93	1.25

This table presents Charles River Laboratories International's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/26/2015	12/31/2016	12/30/2017	12/29/2018	12/28/2019	12/26/2020	12/25/2021	12/31/2022	12/30/2023	12/28/2024	12/27/2025
Total Assets	2,068	2,712	2,930	3,856	4,693	5,491	7,024	7,603	8,195	7,528	7,135
Total Current Assets	559	657	827	898	1,021	1,201	1,274	1,439	1,609	1,403	1,447
Cash & Equivalents	118	118	164	195	238	228	241	234	277	195	214
Accounts Receivable	270	364	430	472	514	618	643	752	780	721	709
Inventories, net	94	96	115	128	161	186	199	256	380	279	299
Prepaid Expenses	30	34	118	102	109	169	191	197	171	209	225
Plant, Property, & Equipment, net	678	756	782	933	1,044	0.00	1,291	1,466	1,640	1,604	1,655
Total Noncurrent Assets	831	1,299	1,321	2,025	2,627	4,290	4,459	4,698	4,947	4,521	4,033
Long-Term Investments	-	-	-	-	-	-	201	312	244	218	207
Goodwill	439	788	805	1,247	1,541	1,809	2,712	2,850	3,095	2,847	2,764
Intangible Assets	281	394	370	611	689	788	1,061	955	864	723	340
Noncurrent Deferred & Refundable Income Taxes	40	29	23	23	45	38	40	41	40	42	67
Other Noncurrent Operating Assets	72	88	124	144	213	1,477	444	540	703	691	655
Total Liabilities & Shareholders' Equity	2,068	2,712	2,930	3,856	4,693	5,491	7,024	7,603	8,195	7,528	7,135
Total Liabilities	1,303	1,858	1,866	2,518	3,026	3,347	4,432	4,579	4,536	4,020	3,924
Total Current Liabilities	312	430	464	558	710	840	1,033	1,092	1,055	994	1,120
Accounts Payable	37	68	78	66	111	122	198	206	169	140	149
Accrued Expenses	89	84	90	107	139	150	229	220	228	232	270
Current Deferred Revenue	81	128	118	145	172	208	220	264	242	248	210
Current Employee Benefit Liabilities	73	93	101	137	159	207	246	197	213	179	269
Other Current Liabilities	13	27	44	71	91	102	140	205	203	194	222
Total Noncurrent Liabilities	991	1,428	1,402	1,959	2,316	2,507	3,399	3,488	3,481	3,026	2,804
Long-Term Debt	846	1,208	1,114	1,637	1,850	1,930	2,664	2,708	2,647	2,240	2,136
Noncurrent Deferred & Payable Income Tax Liabilities	48	56	90	144	167	217	240	216	191	107	95
Other Noncurrent Operating Liabilities	89	159	195	179	299	361	496	565	642	679	572
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	28	15	17	19	29	25	53	42	57	41	41
Total Equity & Noncontrolling Interests	738	839	1,047	1,320	1,638	2,118	2,539	2,981	3,602	3,467	3,170
Total Preferred & Common Equity	733	837	1,045	1,317	1,635	2,115	2,535	2,976	3,597	3,462	3,165
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	733	837	1,045	1,317	1,635	2,115	2,535	2,976	3,597	3,462	3,165
Common Stock	2,399	2,478	2,561	1,448	1,532	1,628	1,719	1,805	1,906	1,967	1,948
Retained Earnings	11	165	289	42	280	625	981	1,433	1,887	1,812	1,389
Treasury Stock	-1,541	-1,553	-1,660	-0.06	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accumulated Other Comprehensive Income / (Loss)	-136	-254	-145	-173	-178	-139	-165	-262	-196	-317	-172
Noncontrolling Interest	4.49	2.36	2.33	2.45	3.24	3.57	4.16	4.79	5.39	5.45	5.30

This table presents Charles River Laboratories International's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	7/1/2023	9/30/2023	12/30/2023	3/30/2024	6/29/2024	9/28/2024	12/28/2024	3/29/2025	6/28/2025	9/27/2025	3/28/2026
Total Assets	7,772	7,607	8,195	8,153	7,948	8,004	7,528	7,582	7,561	7,514	7,730
Total Current Assets	1,505	1,444	1,609	1,668	1,499	1,495	1,403	1,506	1,470	1,532	1,489
Cash & Equivalents	200	157	277	327	179	210	195	229	183	207	192
Accounts Receivable	801	799	780	787	762	754	721	757	768	734	700
Inventories, net	285	293	380	361	349	336	279	290	280	303	360
Prepaid Expenses	218	195	171	193	209	194	209	230	240	288	237
Plant, Property, & Equipment, net	1,530	1,525	1,640	1,619	1,614	1,640	1,604	1,587	1,607	1,592	1,510
Total Noncurrent Assets	4,738	4,637	4,947	4,866	4,835	4,869	4,521	4,489	4,484	4,390	4,731
Long-Term Investments	300	302	244	244	232	236	218	214	216	195	210
Goodwill	2,917	2,885	3,095	3,070	3,080	3,125	2,847	2,873	2,936	2,922	3,040
Intangible Assets	930	886	864	828	800	778	723	656	602	571	249
Noncurrent Deferred & Refundable Income Taxes	39	34	40	37	36	38	42	49	47	37	89
Other Noncurrent Operating Assets	553	530	703	688	687	692	691	697	682	665	1,144
Total Liabilities & Shareholders' Equity	7,772	7,607	8,195	8,153	7,948	8,004	7,528	7,582	7,561	7,514	7,730
Total Liabilities	4,472	4,256	4,536	4,449	4,175	4,176	4,020	4,341	4,161	4,063	4,742
Total Current Liabilities	1,008	994	1,055	955	948	1,012	994	1,051	1,080	1,122	1,094
Accounts Payable	140	136	169	130	133	136	140	149	146	170	134
Accrued Expenses	221	198	228	191	192	208	232	242	232	229	372
Current Deferred Revenue	257	250	242	256	247	252	248	250	268	238	194
Current Employee Benefit Liabilities	191	224	213	190	177	211	179	197	228	270	167
Other Current Liabilities	199	185	203	188	198	205	194	211	207	216	226
Total Noncurrent Liabilities	3,465	3,262	3,481	3,494	3,228	3,164	3,026	3,290	3,081	2,941	3,648
Long-Term Debt	2,678	2,514	2,647	2,660	2,409	2,327	2,240	2,511	2,332	2,185	2,663
Noncurrent Deferred & Payable Income Tax Liabilities	207	185	191	180	165	168	107	107	109	123	81
Other Noncurrent Operating Liabilities	579	563	642	653	653	670	679	672	639	633	904
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	42	40	57	58	46	41	41	42	40	40	42
Total Equity & Noncontrolling Interests	3,258	3,311	3,602	3,646	3,727	3,787	3,467	3,200	3,360	3,410	2,946
Total Preferred & Common Equity	3,252	3,306	3,597	3,640	3,723	3,782	3,462	3,194	3,353	3,405	2,941
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	3,252	3,306	3,597	3,640	3,723	3,782	3,462	3,194	3,353	3,405	2,941
Common Stock	1,851	1,878	1,906	1,940	1,957	1,972	1,967	1,979	1,993	2,016	1,968
Retained Earnings	1,633	1,720	1,887	1,960	2,054	2,123	1,812	1,838	1,890	1,944	1,374
Treasury Stock	-24	-24	0.00	-9.35	-18	-120	0.00	-357	-363	-363	-210
Accumulated Other Comprehensive Income / (Loss)	-208	-268	-196	-250	-270	-193	-317	-265	-166	-192	-191
Noncontrolling Interest	5.85	4.77	5.39	5.72	4.29	4.85	5.45	5.78	6.31	4.88	5.82

This table displays calculated financial ratios and metrics derived from Charles River Laboratories International's official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/26/2015	12/31/2016	12/30/2017	12/29/2018	12/28/2019	12/26/2020	12/25/2021	12/31/2022	12/30/2023	12/28/2024	12/27/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	5.06%	23.34%	10.48%	21.99%	15.67%	11.55%	21.08%	12.31%	3.86%	-1.92%	-0.85%
EBITDA Growth	6.20%	23.54%	21.60%	10.77%	10.88%	36.70%	6.76%	20.24%	4.22%	-44.24%	-29.11%
EBIT Growth	11.18%	19.03%	30.77%	5.70%	5.46%	46.57%	3.99%	23.02%	4.59%	-70.42%	-98.77%
NOPAT Growth	23.57%	3.56%	-26.70%	119.25%	9.75%	20.51%	38.42%	5.18%	-0.90%	-87.89%	-71.48%
Net Income Growth	17.85%	3.49%	-19.77%	82.32%	11.08%	43.79%	9.18%	23.51%	-2.48%	-94.74%	-662.11%
EPS Growth	17.67%	3.19%	-21.36%	81.89%	9.74%	42.01%	5.56%	24.74%	-2.74%	-97.83%	-1,555.00%
Operating Cash Flow Growth	21.70%	3.28%	0.37%	38.69%	9.02%	13.65%	39.19%	-18.55%	10.37%	7.41%	0.42%
Free Cash Flow Firm Growth	-116.52%	-802.84%	116.93%	-1,096.99%	56.87%	-5.83%	-90.64%	133.18%	-163.25%	669.25%	-16.77%
Invested Capital Growth	14.53%	30.14%	3.67%	37.04%	17.99%	17.44%	23.57%	7.74%	11.57%	-7.78%	-7.66%
Revenue Q/Q Growth	1.81%	7.20%	0.63%	5.74%	3.54%	3.54%	3.33%	5.15%	-2.05%	-0.27%	-0.21%
EBITDA Q/Q Growth	2.72%	7.86%	0.79%	4.80%	9.31%	12.50%	-2.88%	13.18%	-3.36%	-41.70%	-20.52%
EBIT Q/Q Growth	5.50%	7.50%	1.77%	4.58%	11.53%	16.71%	-5.24%	18.11%	-5.15%	-67.15%	-96.90%
NOPAT Q/Q Growth	3.81%	9.48%	-39.64%	83.08%	-0.43%	8.03%	8.82%	-4.70%	1.14%	-85.83%	-82.14%
Net Income Q/Q Growth	3.20%	8.97%	-37.19%	64.01%	8.69%	21.11%	-1.08%	11.12%	-0.03%	-94.09%	-78.55%
EPS Q/Q Growth	2.96%	9.12%	-38.05%	66.79%	8.57%	19.80%	-1.81%	11.66%	-0.32%	-97.50%	-92.72%
Operating Cash Flow Q/Q Growth	7.38%	-0.72%	1.79%	3.70%	9.25%	-7.18%	13.57%	0.90%	-1.98%	-7.73%	-1.58%
Free Cash Flow Firm Q/Q Growth	-267.52%	21.87%	-66.00%	13.23%	-5.17%	-306.75%	57.08%	-47.29%	-117.44%	283.81%	-25.54%
Invested Capital Q/Q Growth	-0.23%	-3.45%	-2.61%	-0.31%	0.01%	5.31%	-6.49%	-4.28%	7.02%	-6.53%	-5.88%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	38.96%	38.30%	37.73%	37.07%	36.56%	36.72%	37.70%	36.79%	36.39%	32.88%	32.96%
EBITDA Margin	22.32%	22.36%	24.61%	22.35%	21.42%	26.25%	23.15%	24.78%	24.87%	14.14%	10.11%
Operating Margin	15.14%	14.13%	15.52%	14.62%	13.40%	14.80%	16.66%	16.37%	14.95%	5.61%	0.63%
EBIT Margin	15.36%	14.83%	17.55%	15.21%	13.87%	18.22%	15.65%	17.14%	17.26%	5.21%	0.06%
Profit (Net Income) Margin	11.08%	9.30%	6.75%	10.09%	9.69%	12.49%	11.27%	12.39%	11.63%	0.62%	-3.54%
Tax Burden Percent	77.31%	70.14%	42.25%	81.20%	83.55%	81.70%	82.97%	79.07%	82.64%	27.16%	142.87%
Interest Burden Percent	93.30%	89.41%	91.08%	81.73%	83.67%	83.93%	86.78%	91.41%	81.55%	44.17%	-3,847.76%
Effective Tax Rate	22.20%	29.98%	57.71%	19.34%	16.45%	18.30%	17.03%	20.93%	17.36%	72.84%	0.00%
Return on Invested Capital (ROIC)	11.28%	9.51%	6.05%	11.00%	9.58%	9.81%	11.24%	10.30%	9.30%	1.11%	0.34%
ROIC Less NNEP Spread (ROIC-NNEP)	9.90%	8.45%	6.39%	7.86%	7.06%	10.50%	6.68%	9.29%	7.91%	-0.73%	-8.68%
Return on Net Nonoperating Assets (RNNOA)	9.28%	9.80%	7.03%	8.05%	7.33%	9.37%	5.60%	7.25%	5.08%	-0.40%	-4.57%
Return on Equity (ROE)	20.56%	19.31%	13.08%	19.04%	16.91%	19.18%	16.84%	17.54%	14.38%	0.71%	-4.23%
Cash Return on Invested Capital (CROIC)	-2.27%	-16.68%	2.45%	-20.26%	-6.93%	-6.23%	-9.84%	2.84%	-1.64%	9.21%	8.30%
Operating Return on Assets (OROA)	10.63%	10.43%	11.56%	10.16%	8.50%	10.46%	8.85%	9.32%	9.02%	2.68%	0.04%
Return on Assets (ROA)	7.67%	6.54%	4.45%	6.74%	5.94%	7.17%	6.37%	6.74%	6.08%	0.32%	-1.94%
Return on Common Equity (ROCE)	19.65%	18.72%	12.84%	18.73%	16.61%	18.87%	16.54%	17.22%	14.14%	0.70%	-4.17%
Return on Equity Simple (ROE_SIMPLE)	20.61%	18.69%	12.00%	17.36%	15.54%	17.28%	15.73%	16.55%	13.36%	0.73%	0.00%
Net Operating Profit after Tax (NOPAT)	161	166	122	267	293	354	489	515	510	62	18
NOPAT Margin	11.78%	9.89%	6.56%	11.80%	11.19%	12.09%	13.82%	12.95%	12.35%	1.52%	0.44%
Net Nonoperating Expense Percent (NNEP)	1.38%	1.06%	-0.33%	3.14%	2.52%	-0.69%	4.56%	1.01%	1.39%	1.84%	9.02%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	9.05%	8.16%	1.08%	0.33%
Cost of Revenue to Revenue	61.04%	61.70%	62.27%	62.93%	63.44%	63.28%	62.30%	63.21%	63.61%	67.12%	67.04%
SG&A Expenses to Revenue	22.04%	21.69%	19.99%	19.59%	19.75%	18.09%	17.51%	16.73%	18.11%	18.54%	18.51%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	23.81%	24.17%	22.21%	22.45%	23.16%	21.92%	21.04%	20.41%	21.44%	27.27%	32.33%
Earnings before Interest and Taxes (EBIT)	209	249	326	345	363	533	554	681	713	211	2.59
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	304	376	457	506	562	768	820	985	1,027	573	406
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	5.09	4.31	4.96	4.08	4.54	5.92	7.35	3.72	3.37	2.75	3.17
Price to Tangible Book Value (P/TBV)	277.92	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	166.00
Price to Revenue (P/Rev)	2.74	2.14	2.79	2.37	2.83	4.28	5.26	2.79	2.94	2.35	2.50
Price to Earnings (P/E)	25.01	23.30	42.02	23.74	29.44	34.37	47.65	22.80	25.55	428.75	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	4.00%	4.29%	2.38%	4.21%	3.40%	2.91%	2.10%	4.39%	3.91%	0.23%	0.00%
Enterprise Value to Invested Capital (EV/IC)	2.97	2.40	3.02	2.44	2.74	3.67	4.34	2.56	2.47	2.14	2.39
Enterprise Value to Revenue (EV/Rev)	3.31	2.82	3.33	3.03	3.47	4.89	5.91	3.34	3.47	2.81	2.94
Enterprise Value to EBITDA (EV/EBITDA)	14.82	12.61	13.53	13.56	16.21	18.63	25.51	13.49	13.94	19.90	29.04
Enterprise Value to EBIT (EV/EBIT)	21.54	19.01	18.97	19.92	25.04	26.85	37.75	19.51	20.08	54.04	4,557.39
Enterprise Value to NOPAT (EV/NOPAT)	28.09	28.50	50.72	25.69	31.02	40.45	42.73	25.83	28.06	184.51	669.12
Enterprise Value to Operating Cash Flow (EV/OCF)	14.70	14.96	19.44	15.57	18.93	26.17	27.48	21.46	20.93	15.51	15.98
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	125.19	0.00	0.00	0.00	0.00	93.50	0.00	22.25	27.66
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.13	1.45	1.08	1.25	1.13	0.92	1.03	0.90	0.72	0.64	0.67
Long-Term Debt to Equity	1.11	1.41	1.05	1.22	1.11	0.90	1.03	0.90	0.72	0.64	0.67
Financial Leverage	0.94	1.16	1.10	1.02	1.04	0.89	0.84	0.78	0.64	0.55	0.53
Leverage Ratio	2.68	2.95	2.94	2.82	2.85	2.67	2.64	2.60	2.36	2.19	2.18
Compound Leverage Factor	2.50	2.64	2.68	2.31	2.38	2.24	2.29	2.38	1.93	0.97	-83.97
Debt to Total Capital	52.99%	59.13%	51.84%	55.48%	53.12%	48.01%	50.68%	47.24%	41.98%	38.97%	39.95%
Short-Term Debt to Total Capital	1.05%	1.31%	1.40%	1.05%	1.08%	1.22%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	51.95%	57.82%	50.43%	54.44%	52.03%	46.80%	50.68%	47.24%	41.98%	38.97%	39.95%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	2.00%	0.81%	0.86%	0.70%	0.90%	0.70%	1.09%	0.82%	0.99%	0.81%	0.87%
Common Equity to Total Capital	45.01%	40.06%	47.31%	43.82%	45.98%	51.28%	48.23%	51.93%	57.04%	60.22%	59.18%
Debt to EBITDA	2.84	3.28	2.50	3.29	3.36	2.58	3.25	2.75	2.58	3.91	5.26
Net Debt to EBITDA	2.45	2.97	2.15	2.91	2.94	2.28	2.71	2.19	2.07	3.19	4.23
Long-Term Debt to EBITDA	2.78	3.21	2.44	3.23	3.29	2.51	3.25	2.75	2.58	3.91	5.26
Debt to NOPAT	5.37	7.43	9.39	6.24	6.44	5.60	5.44	5.26	5.19	36.28	121.29
Net Debt to NOPAT	4.64	6.72	8.05	5.51	5.62	4.95	4.54	4.20	4.17	29.59	97.40
Long-Term Debt to NOPAT	5.27	7.26	9.14	6.12	6.30	5.46	5.44	5.26	5.19	36.28	121.29
Altman Z-Score	2.86	2.27	2.95	2.28	2.45	3.34	3.52	2.59	2.80	2.45	2.42
Noncontrolling Interest Sharing Ratio	4.40%	3.06%	1.87%	1.66%	1.76%	1.60%	1.82%	1.86%	1.64%	1.52%	1.39%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.79	1.53	1.78	1.61	1.44	1.43	1.23	1.32	1.52	1.41	1.29
Quick Ratio	1.24	1.12	1.28	1.20	1.06	1.01	0.86	0.90	1.00	0.92	0.82
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-32	-292	49	-492	-212	-225	-429	142	-90	512	426
Operating Cash Flow to CapEx	485.10%	573.18%	385.87%	314.98%	342.27%	328.16%	332.56%	190.82%	214.71%	315.31%	336.59%
Free Cash Flow to Firm to Interest Expense	-2.14	-10.53	1.66	-7.72	-3.49	-2.60	-5.80	2.40	-0.66	4.05	3.98
Operating Cash Flow to Interest Expense	20.36	11.44	10.68	6.92	7.90	6.32	10.29	10.45	5.00	5.82	6.89
Operating Cash Flow Less CapEx to Interest Expense	16.16	9.44	7.91	4.72	5.59	4.40	7.20	4.97	2.67	3.97	4.84
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.69	0.70	0.66	0.67	0.61	0.57	0.57	0.54	0.52	0.52	0.55
Accounts Receivable Turnover	5.16	5.30	4.68	5.02	5.32	5.17	5.62	5.70	5.39	5.40	5.62
Inventory Turnover	9.11	10.95	10.97	11.74	11.53	10.68	11.46	11.05	8.26	8.25	9.32
Fixed Asset Turnover	2.01	2.35	2.42	2.64	2.65	0.00	0.00	2.88	2.66	2.50	2.46
Accounts Payable Turnover	23.61	19.73	15.81	19.79	18.71	15.82	13.76	12.44	14.02	17.58	18.62
Days Sales Outstanding (DSO)	70.69	68.83	78.01	72.66	68.67	70.64	64.99	64.04	67.74	67.65	64.98
Days Inventory Outstanding (DIO)	40.08	33.35	33.26	31.08	31.67	34.16	31.84	33.03	44.19	44.23	39.16
Days Payable Outstanding (DPO)	15.46	18.50	23.09	18.44	19.51	23.08	26.53	29.34	26.04	20.76	19.60
Cash Conversion Cycle (CCC)	95.31	83.67	88.18	85.30	80.83	81.72	70.30	67.74	85.89	91.12	84.54
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,520	1,979	2,051	2,811	3,317	3,895	4,813	5,186	5,786	5,335	4,927
Invested Capital Turnover	0.96	0.96	0.92	0.93	0.86	0.81	0.81	0.80	0.75	0.73	0.78
Increase / (Decrease) in Invested Capital	193	458	73	760	506	578	918	373	600	-450	-409
Enterprise Value (EV)	4,511	4,740	6,184	6,867	9,102	14,301	20,910	13,296	14,315	11,393	11,785
Market Capitalization	3,734	3,606	5,184	5,373	7,420	12,521	18,631	11,086	12,127	9,520	10,023
Book Value per Share	$15.72	$17.68	$22.07	$27.39	$33.47	$42.51	$50.23	$58.50	$70.12	$67.69	$64.30
Tangible Book Value per Share	$0.29	($7.29)	($2.74)	($11.24)	($12.19)	($9.69)	($24.54)	($16.29)	($7.06)	($2.12)	$1.23
Total Capital	1,629	2,089	2,209	3,006	3,555	4,123	5,256	5,731	6,306	5,748	5,348
Total Debt	863	1,235	1,145	1,668	1,888	1,980	2,664	2,708	2,647	2,240	2,136
Total Long-Term Debt	846	1,208	1,114	1,637	1,850	1,930	2,664	2,708	2,647	2,240	2,136
Net Debt	745	1,117	981	1,473	1,650	1,751	2,221	2,162	2,127	1,827	1,716
Capital Expenditures (CapEx)	63	55	82	140	141	167	229	325	319	233	219
Debt-free, Cash-free Net Working Capital (DFCFNWC)	147	137	230	176	112	183	-0.30	114	277	214	113
Debt-free Net Working Capital (DFNWC)	265	255	394	371	350	412	241	347	554	409	327
Net Working Capital (NWC)	247	227	363	340	311	361	241	347	554	409	327
Net Nonoperating Expense (NNE)	9.52	9.96	-3.53	39	39	-12	91	22	30	36	160
Net Nonoperating Obligations (NNO)	755	1,125	987	1,473	1,650	1,751	2,221	2,162	2,127	1,827	1,716
Total Depreciation and Amortization (D&A)	95	127	131	162	198	235	266	304	314	362	403
Debt-free, Cash-free Net Working Capital to Revenue	10.75%	8.14%	12.40%	7.75%	4.26%	6.26%	-0.01%	2.86%	6.70%	5.29%	2.81%
Debt-free Net Working Capital to Revenue	19.40%	15.14%	21.22%	16.37%	13.34%	14.08%	6.81%	8.74%	13.41%	10.10%	8.14%
Net Working Capital to Revenue	18.15%	13.51%	19.55%	14.99%	11.87%	12.36%	6.81%	8.74%	13.41%	10.10%	8.14%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$3.21	$3.29	$2.60	$4.72	$5.17	$7.35	$7.77	$9.57	$9.27	$0.20	($2.91)
Adjusted Weighted Average Basic Shares Outstanding	46.72M	47.37M	47.43M	47.95M	48.73M	49.55M	50.29M	50.81M	51.23M	51.38M	49.56M
Adjusted Diluted Earnings per Share	$3.13	$3.23	$2.54	$4.62	$5.07	$7.20	$7.60	$9.48	$9.22	$0.20	($2.91)
Adjusted Weighted Average Diluted Shares Outstanding	46.72M	47.37M	47.43M	49.02M	49.69M	50.61M	51.43M	51.30M	51.45M	51.63M	49.56M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$4.72	$5.17	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	46.72M	47.37M	47.43M	48.23M	48.96M	49.78M	50.49M	50.99M	51.35M	51.14M	49.23M
Normalized Net Operating Profit after Tax (NOPAT)	161	166	202	267	293	354	489	515	510	310	281
Normalized NOPAT Margin	11.78%	9.89%	10.86%	11.80%	11.19%	12.09%	13.82%	12.95%	12.35%	7.65%	6.99%
Pre Tax Income Margin	14.33%	13.26%	15.99%	12.43%	11.60%	15.29%	13.58%	15.67%	14.08%	2.30%	-2.48%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	13.90	9.00	10.95	5.40	5.97	6.16	7.50	11.49	5.21	1.67	0.02
NOPAT to Interest Expense	10.66	6.00	4.09	4.19	4.82	4.09	6.62	8.68	3.73	0.49	0.16
EBIT Less CapEx to Interest Expense	9.70	7.00	8.18	3.21	3.66	4.24	4.40	6.02	2.88	-0.18	-2.02
NOPAT Less CapEx to Interest Expense	6.46	4.01	1.33	2.00	2.51	2.16	3.53	3.20	1.40	-1.36	-1.88
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	77.76%	7.85%	85.22%	6.05%	7.12%	6.56%	10.21%	7.85%	5.03%	471.22%	-253.70%

This table displays calculated financial ratios and metrics derived from Charles River Laboratories International's official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/30/2023	3/30/2024	6/29/2024	9/28/2024	12/28/2024	3/29/2025	6/28/2025	9/27/2025	12/27/2025	3/28/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	-	49,227,800.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	49,227,800.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-0.30
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	3.79%	-7.85%	-1.73%	-3.19%	-1.64%	-1.08%	-2.71%	0.59%	-0.49%	-0.83%	1.19%
EBITDA Growth	7.25%	-10.01%	-10.14%	-1.86%	-7.10%	-127.49%	-15.82%	-6.67%	-5.69%	-118.68%	-65.59%
EBIT Growth	8.10%	-13.85%	-19.93%	-7.93%	-17.38%	-179.11%	-52.62%	-32.88%	-7.35%	-42.52%	-106.78%
NOPAT Growth	-1.31%	-4.85%	-28.85%	-6.29%	-23.44%	-197.54%	-43.33%	-38.16%	-5.76%	-69.03%	56.27%
Net Income Growth	-9.83%	-0.08%	-28.35%	-5.21%	-20.14%	-213.12%	-65.26%	-44.10%	-20.97%	-29.26%	-157.20%
EPS Growth	-10.11%	-0.82%	-35.32%	-7.94%	-21.30%	-214.88%	-61.54%	-39.08%	-17.29%	-33.57%	-160.00%
Operating Cash Flow Growth	54.73%	-5.88%	18.75%	30.66%	22.56%	-27.87%	32.19%	5.72%	-15.08%	-7.43%	-76.08%
Free Cash Flow Firm Growth	186.05%	-94.96%	-78.76%	-222.58%	-263.45%	169.39%	283.23%	394.07%	363.82%	-36.88%	-73.40%
Invested Capital Growth	-0.21%	11.57%	7.19%	5.36%	5.59%	-7.78%	-8.36%	-7.60%	-8.30%	-7.66%	-1.12%
Revenue Q/Q Growth	-3.14%	-1.28%	-0.19%	1.44%	-1.59%	-0.71%	-1.83%	4.87%	-2.64%	-1.06%	0.16%
EBITDA Q/Q Growth	-6.60%	43.31%	-32.38%	8.44%	-11.59%	-142.41%	307.07%	20.22%	-10.67%	-198.33%	132.59%
EBIT Q/Q Growth	-10.50%	65.70%	-45.23%	13.35%	-19.69%	-258.66%	132.80%	60.57%	10.86%	-344.05%	98.44%
NOPAT Q/Q Growth	-7.33%	1.86%	-21.25%	26.07%	-24.29%	-229.77%	145.75%	37.56%	15.38%	-332.75%	142.30%
Net Income Q/Q Growth	-11.49%	114.67%	-60.58%	26.56%	-25.43%	-404.07%	112.11%	103.62%	5.43%	-597.32%	94.64%
EPS Q/Q Growth	-10.58%	114.79%	-64.19%	33.85%	-23.56%	-413.53%	111.99%	112.00%	3.77%	-606.36%	94.61%
Operating Cash Flow Q/Q Growth	38.70%	7.54%	-41.21%	49.00%	30.10%	-36.71%	7.74%	19.17%	4.51%	-31.01%	-72.16%
Free Cash Flow Firm Q/Q Growth	-8.79%	-470.09%	38.75%	40.72%	-21.63%	257.12%	61.74%	-4.85%	9.12%	-62.41%	-31.85%
Invested Capital Q/Q Growth	-1.31%	7.02%	0.14%	-0.39%	-1.09%	-6.53%	-0.49%	0.45%	-1.85%	-5.88%	6.56%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	35.25%	35.92%	34.09%	34.47%	34.56%	28.35%	32.28%	34.60%	33.72%	31.15%	29.59%
EBITDA Margin	21.83%	31.69%	21.47%	22.95%	20.62%	-8.81%	18.58%	21.30%	19.54%	-19.42%	6.32%
Operating Margin	14.76%	13.12%	12.45%	14.78%	11.63%	-16.73%	7.59%	9.70%	13.32%	-28.51%	12.04%
EBIT Margin	14.15%	23.75%	13.03%	14.56%	11.88%	-18.99%	6.35%	9.72%	11.06%	-27.29%	-0.43%
Profit (Net Income) Margin	8.57%	18.64%	7.36%	9.19%	6.96%	-21.32%	2.63%	5.11%	5.53%	-27.79%	-1.49%
Tax Burden Percent	77.98%	90.54%	75.23%	78.78%	77.04%	98.60%	71.93%	73.78%	63.71%	93.94%	49.44%
Interest Burden Percent	77.71%	86.72%	75.12%	80.08%	76.04%	113.87%	57.60%	71.21%	78.43%	108.39%	707.35%
Effective Tax Rate	22.02%	9.47%	24.77%	21.22%	22.96%	0.00%	28.07%	26.22%	36.29%	0.00%	0.00%
Return on Invested Capital (ROIC)	8.97%	8.94%	6.88%	8.44%	6.55%	-8.53%	3.95%	5.19%	6.24%	-15.62%	6.43%
ROIC Less NNEP Spread (ROIC-NNEP)	7.71%	12.14%	5.94%	7.23%	5.52%	-13.40%	2.62%	4.12%	4.62%	-20.01%	1.87%
Return on Net Nonoperating Assets (RNNOA)	6.15%	7.79%	3.76%	4.27%	3.03%	-7.39%	1.57%	2.26%	2.33%	-10.55%	1.30%
Return on Equity (ROE)	15.11%	16.73%	10.64%	12.71%	9.57%	-15.92%	5.52%	7.45%	8.56%	-26.17%	7.73%
Cash Return on Invested Capital (CROIC)	9.53%	-1.64%	1.50%	3.02%	2.40%	9.21%	6.27%	9.46%	10.46%	8.30%	2.06%
Operating Return on Assets (OROA)	7.96%	12.41%	6.76%	7.55%	6.18%	-9.78%	3.24%	5.05%	5.74%	-14.95%	-0.22%
Return on Assets (ROA)	4.82%	9.75%	3.82%	4.77%	3.62%	-10.98%	1.34%	2.65%	2.87%	-15.22%	-0.78%
Return on Common Equity (ROCE)	14.89%	16.45%	10.46%	12.53%	9.45%	-15.68%	5.43%	7.35%	8.46%	-25.81%	7.61%
Return on Equity Simple (ROE_SIMPLE)	14.53%	0.00%	12.39%	11.97%	11.32%	0.00%	-0.73%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	118	120	95	119	90	-117	54	74	85	-198	84
NOPAT Margin	11.51%	11.87%	9.37%	11.64%	8.96%	-11.71%	5.46%	7.16%	8.48%	-19.96%	8.43%
Net Nonoperating Expense Percent (NNEP)	1.26%	-3.20%	0.94%	1.21%	1.02%	4.87%	1.34%	1.08%	1.62%	4.40%	4.56%
Return On Investment Capital (ROIC_SIMPLE)	-	1.93%	-	-	-	-2.06%	0.94%	1.30%	1.52%	-3.74%	1.50%
Cost of Revenue to Revenue	64.75%	64.08%	65.91%	65.53%	65.44%	71.65%	67.72%	65.41%	66.28%	68.85%	70.41%
SG&A Expenses to Revenue	17.15%	19.45%	18.42%	16.55%	19.73%	19.52%	18.07%	18.56%	17.67%	19.73%	16.01%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	20.49%	22.81%	21.64%	19.69%	22.94%	45.08%	24.70%	24.89%	20.40%	59.66%	17.55%
Earnings before Interest and Taxes (EBIT)	145	241	132	149	120	-190	62	100	111	-271	-4.23
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	224	321	217	235	208	-88	183	220	196	-193	63
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.04	3.37	3.82	2.86	2.71	2.75	2.49	2.20	2.15	3.17	2.66
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	166.00	0.00
Price to Revenue (P/Rev)	2.38	2.94	3.38	2.61	2.52	2.35	1.98	1.83	1.82	2.50	1.95
Price to Earnings (P/E)	21.16	25.55	31.27	24.10	24.16	428.75	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	4.73%	3.91%	3.20%	4.15%	4.14%	0.23%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	2.25	2.47	2.77	2.20	2.13	2.14	1.90	1.75	1.75	2.39	1.93
Enterprise Value to Revenue (EV/Rev)	2.88	3.47	3.90	3.11	3.00	2.81	2.50	2.32	2.27	2.94	2.52
Enterprise Value to EBITDA (EV/EBITDA)	11.43	13.94	16.01	12.72	12.39	19.90	18.71	17.89	17.90	29.04	35.47
Enterprise Value to EBIT (EV/EBIT)	16.17	20.08	23.61	19.02	18.95	54.04	71.18	101.22	109.42	4,557.39	0.00
Enterprise Value to NOPAT (EV/NOPAT)	24.09	28.06	33.99	27.37	27.92	184.51	0.00	107.24	92.66	669.12	205.88
Enterprise Value to Operating Cash Flow (EV/OCF)	17.41	20.93	22.79	16.92	15.28	15.51	12.97	11.87	12.20	15.98	16.71
Enterprise Value to Free Cash Flow (EV/FCFF)	23.55	0.00	191.71	74.62	91.19	22.25	28.92	17.79	15.97	27.66	93.47
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.75	0.72	0.72	0.64	0.61	0.64	0.77	0.69	0.63	0.67	0.89
Long-Term Debt to Equity	0.75	0.72	0.72	0.64	0.61	0.64	0.77	0.69	0.63	0.67	0.89
Financial Leverage	0.80	0.64	0.63	0.59	0.55	0.55	0.60	0.55	0.50	0.53	0.69
Leverage Ratio	2.49	2.36	2.31	2.22	2.17	2.19	2.27	2.16	2.13	2.18	2.46
Compound Leverage Factor	1.93	2.05	1.74	1.78	1.65	2.50	1.31	1.54	1.67	2.37	17.39
Debt to Total Capital	42.87%	41.98%	41.80%	38.97%	37.80%	38.97%	43.65%	40.69%	38.77%	39.95%	47.12%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	42.87%	41.98%	41.80%	38.97%	37.80%	38.97%	43.65%	40.69%	38.77%	39.95%	47.12%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.76%	0.99%	1.00%	0.81%	0.74%	0.81%	0.82%	0.81%	0.80%	0.87%	0.84%
Common Equity to Total Capital	56.37%	57.04%	57.20%	60.21%	61.46%	60.22%	55.53%	58.50%	60.42%	59.18%	52.03%
Debt to EBITDA	2.37	2.58	2.65	2.41	2.37	3.91	4.66	4.46	4.28	5.26	9.31
Net Debt to EBITDA	1.93	2.07	2.08	2.00	1.91	3.19	3.84	3.70	3.49	4.23	7.91
Long-Term Debt to EBITDA	2.37	2.58	2.65	2.41	2.37	3.91	4.66	4.46	4.28	5.26	9.31
Debt to NOPAT	4.98	5.19	5.63	5.20	5.34	36.28	-18.40	26.76	22.16	121.29	54.05
Net Debt to NOPAT	4.07	4.17	4.42	4.31	4.32	29.59	-15.15	22.18	18.08	97.40	45.90
Long-Term Debt to NOPAT	4.98	5.19	5.63	5.20	5.34	36.28	-18.40	26.76	22.16	121.29	54.05
Altman Z-Score	2.42	2.61	2.87	2.55	2.47	2.28	2.07	2.05	2.09	2.30	1.82
Noncontrolling Interest Sharing Ratio	1.49%	1.64%	1.63%	1.39%	1.26%	1.52%	1.60%	1.35%	1.25%	1.39%	1.53%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.45	1.52	1.75	1.58	1.48	1.41	1.43	1.36	1.37	1.29	1.36
Quick Ratio	0.96	1.00	1.17	0.99	0.95	0.92	0.94	0.88	0.84	0.82	0.82
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	130	-480	-294	-174	-212	333	538	512	559	210	143
Operating Cash Flow to CapEx	311.54%	282.09%	164.12%	490.14%	650.27%	210.75%	289.42%	579.64%	600.97%	165.85%	73.47%
Free Cash Flow to Firm to Interest Expense	3.84	-14.30	-8.39	-5.32	-7.00	11.79	19.31	17.09	22.00	8.84	5.35
Operating Cash Flow to Interest Expense	6.09	6.59	3.71	5.91	8.31	5.64	6.16	6.83	8.42	6.20	1.54
Operating Cash Flow Less CapEx to Interest Expense	4.13	4.25	1.45	4.70	7.04	2.97	4.03	5.65	7.02	2.46	-0.55
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.56	0.52	0.52	0.52	0.52	0.52	0.51	0.52	0.52	0.55	0.53
Accounts Receivable Turnover	5.37	5.39	5.22	5.22	5.23	5.40	5.21	5.27	5.41	5.62	5.53
Inventory Turnover	9.66	8.26	8.47	8.36	8.42	8.25	8.34	8.66	8.54	9.32	8.39
Fixed Asset Turnover	2.90	2.66	2.64	2.59	2.57	2.50	2.51	2.50	2.49	2.46	2.60
Accounts Payable Turnover	16.85	14.02	21.16	19.42	19.46	17.58	19.48	19.51	17.84	18.62	19.25
Days Sales Outstanding (DSO)	67.97	67.74	69.92	69.95	69.82	67.65	70.03	69.30	67.52	64.98	66.02
Days Inventory Outstanding (DIO)	37.78	44.19	43.10	43.63	43.34	44.23	43.74	42.17	42.77	39.16	43.49
Days Payable Outstanding (DPO)	21.67	26.04	17.25	18.80	18.76	20.76	18.74	18.71	20.46	19.60	18.96
Cash Conversion Cycle (CCC)	84.08	85.89	95.77	94.78	94.40	91.12	95.04	92.76	89.83	84.54	90.56
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	5,406	5,786	5,794	5,771	5,708	5,335	5,309	5,333	5,235	4,927	5,250
Invested Capital Turnover	0.78	0.75	0.73	0.73	0.73	0.73	0.72	0.73	0.74	0.78	0.76
Increase / (Decrease) in Invested Capital	-11	600	389	294	302	-450	-485	-438	-474	-409	-59
Enterprise Value (EV)	12,148	14,315	16,052	12,690	12,165	11,393	10,070	9,348	9,140	11,785	10,144
Market Capitalization	10,048	12,127	13,899	10,641	10,239	9,520	7,955	7,368	7,311	10,023	7,835
Book Value per Share	$64.48	$70.12	$70.77	$72.27	$73.26	$67.69	$62.46	$68.27	$69.20	$64.30	$59.73
Tangible Book Value per Share	($9.07)	($7.06)	($5.01)	($3.05)	($2.34)	($2.12)	($6.55)	($3.77)	($1.79)	$1.23	($7.08)
Total Capital	5,865	6,306	6,364	6,182	6,154	5,748	5,753	5,732	5,636	5,348	5,651
Total Debt	2,514	2,647	2,660	2,409	2,327	2,240	2,511	2,332	2,185	2,136	2,663
Total Long-Term Debt	2,514	2,647	2,660	2,409	2,327	2,240	2,511	2,332	2,185	2,136	2,663
Net Debt	2,055	2,127	2,090	1,998	1,880	1,827	2,067	1,933	1,784	1,716	2,262
Capital Expenditures (CapEx)	66	78	79	39	39	76	59	35	36	89	56
Debt-free, Cash-free Net Working Capital (DFCFNWC)	293	277	386	373	272	214	226	207	203	113	203
Debt-free Net Working Capital (DFNWC)	451	554	713	552	483	409	455	389	410	327	395
Net Working Capital (NWC)	451	554	713	552	483	409	455	389	410	327	395
Net Nonoperating Expense (NNE)	30	-69	20	25	20	96	28	21	30	78	99
Net Nonoperating Obligations (NNO)	2,055	2,127	2,090	1,998	1,880	1,827	2,067	1,933	1,784	1,716	2,262
Total Depreciation and Amortization (D&A)	79	81	85	86	88	102	120	120	85	78	67
Debt-free, Cash-free Net Working Capital to Revenue	6.96%	6.70%	9.40%	9.14%	6.71%	5.29%	5.62%	5.13%	5.05%	2.81%	5.05%
Debt-free Net Working Capital to Revenue	10.69%	13.41%	17.35%	13.53%	11.88%	10.10%	11.32%	9.67%	10.20%	8.14%	9.81%
Net Working Capital to Revenue	10.69%	13.41%	17.35%	13.53%	11.88%	10.10%	11.32%	9.67%	10.20%	8.14%	9.81%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$1.70	$3.66	$1.31	$1.75	$1.34	($4.20)	$0.50	$1.06	$1.11	($5.58)	($0.30)
Adjusted Weighted Average Basic Shares Outstanding	51.28M	51.23M	51.44M	51.55M	51.39M	51.38M	50.68M	49.15M	49.21M	49.56M	48.95M
Adjusted Diluted Earnings per Share	$1.69	$3.63	$1.30	$1.74	$1.33	($4.17)	$0.50	$1.06	$1.10	($5.57)	($0.30)
Adjusted Weighted Average Diluted Shares Outstanding	51.61M	51.45M	51.84M	51.85M	51.58M	51.63M	50.85M	49.32M	49.43M	49.56M	48.95M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	51.30M	51.35M	51.51M	51.63M	51.14M	51.14M	49.12M	49.21M	49.22M	49.23M	48.17M
Normalized Net Operating Profit after Tax (NOPAT)	118	120	95	119	90	-117	54	74	85	-198	84
Normalized NOPAT Margin	11.51%	11.87%	9.37%	11.64%	8.96%	-11.71%	5.46%	7.16%	8.48%	-19.96%	8.43%
Pre Tax Income Margin	10.99%	20.59%	9.79%	11.66%	9.04%	-21.62%	3.66%	6.92%	8.68%	-29.58%	-3.01%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	4.30	7.17	3.77	4.56	3.96	-6.74	2.24	3.35	4.38	-11.41	-0.16
NOPAT to Interest Expense	3.50	3.59	2.71	3.65	2.99	-4.16	1.93	2.47	3.36	-8.35	3.14
EBIT Less CapEx to Interest Expense	2.35	4.84	1.50	3.35	2.68	-9.42	0.11	2.17	2.98	-15.15	-2.25
NOPAT Less CapEx to Interest Expense	1.55	1.25	0.45	2.44	1.71	-6.84	-0.20	1.29	1.96	-12.09	1.05
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	5.03%	5.03%	3.21%	4.14%	27.85%	471.22%	-1,985.83%	-711.14%	-453.03%	-253.70%	-118.04%

Financials Breakdown Chart

Key Financial Trends

Here’s a concise trend snapshot for Charles River Laboratories International (NYSE: CRL) based on the last four years of quarterly statements. The focus is on what may matter to retail investors, with items organized from most positive to most negative.

Steady revenue level around $1B per quarter. Across the four years, CRL’s operating and total revenue have consistently hovered near $1.0 billion per quarter (example: Q4 2025 revenue $994.2M; Q3 2025 $1.0049B; Q4 2024 $1.0025B; Q1 2025 $984.2M). This suggests durable demand and a predictable top line.
Consistently positive cash flow from operations. CRL generated solid cash from continuing operating activities in 2025 (Q1 $171.7M; Q2 $204.6M; Q3 $213.8M; Q4 $147.5M) and similar levels in prior years, supporting liquidity even during periods of earnings volatility.
Gross margins generally in the low-to-mid 30% range. Total gross profit in 2025 quarters has typically lined up in the low 300M range against ~1B in revenue (illustrative: Q4 2025 gross profit $309.7M on $994.2M revenue; Q3 2025 $338.8M on $1.005B).
Solid balance sheet with a large but manageable asset base. Total assets typically around $7.5B–$7.6B and total equity in the mid-to-upper $3B range across 2023–2025, with long‑term debt generally in the $2.2B–$2.7B band. This points to a stable capital base and room to fund operations or strategic initiatives.
Earnings per share (EPS) show quarterly volatility but occasional strength. Basic and diluted EPS have been positive in several quarters (for example, Q3 2025 Basic EPS around $1.11 and Q1 2025 around $0.50), though Q4 2025 briefly turned negative (Basic EPS about -$5.58; Diluted about -$5.57). This indicates earnings are not consistently uniform on a quarterly basis.
Significant goodwill and intangible assets on the balance sheet. Noncurrent assets include substantial goodwill (roughly $2.9B–$3.1B) and intangible assets (roughly $0.7B–$1.0B). These levels can imply sensitivity to impairment if market or product dynamics change, even as the company remains cash-flow positive.
Capital structure activity signals ongoing financing adjustments. CRL has engaged in periodic debt issuance and other financing activities across quarters, reflecting ongoing optimization of its capital structure to support operations, acquisitions, or share-related activities.
Q4 2025 shows a large quarterly net loss to common shareholders. Net income attributable to common shareholders was notably negative at about -$276.6M in Q4 2025, with pre-tax income around -$294.1M, signaling a meaningful near-term profitability challenge despite cash-flow strength.
Quarterly earnings volatility including a sharp drop in Q4 2025. The combination of a negative pre-tax income and a large year-end loss points to volatility in quarterly results and potential one-time items or pressures that warrant closer inspection of the operating backdrop and cost structure.
Financing activity and near-term liquidity considerations. In Q4 2025, net cash from financing activities was negative (around -$51.9M), contributing to a tighter financing picture alongside ongoing debt activity and equity movements that investors may want to monitor going forward.

05/15/26 04:01 PM ETAI Generated. May Contain Errors.

Charles River Laboratories International Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Charles River Laboratories International's financial year ends in December. Their financial year 2025 ended on December 27, 2025.

Over the last 10 years, Charles River Laboratories International's net income changed from $151.09 million in 2015 to -$142.16 million in 2025, a change of -194.1%. View Charles River Laboratories International's forecast to see where analysts expect Charles River Laboratories International to go next.

Charles River Laboratories International's total operating income in 2025 was $25.16 million, based on the following breakdown:

Total Gross Profit: $1.32 billion
Total Operating Expenses: $1.30 billion

Over the last 10 years, Charles River Laboratories International's total revenue changed from $1.36 billion in 2015 to $4.02 billion in 2025, a change of 194.5%.

Charles River Laboratories International's total liabilities were at $3.92 billion at the end of 2025, a 2.4% decrease from 2024, and a 201.2% increase since 2015.

In the past 10 years, Charles River Laboratories International's cash and equivalents has ranged from $117.63 million in 2016 to $276.77 million in 2023, and is currently $213.77 million as of their latest financial filing in 2025.

Over the last 10 years, Charles River Laboratories International's book value per share changed from 15.72 in 2015 to 64.30 in 2025, a change of 309.0%.

Related Companies

Financial statements for NYSE:CRL last updated on 5/8/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Charles River Laboratories International (CRL) Financials

Financials Breakdown Chart

Key Financial Trends

Charles River Laboratories International Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Charles River Laboratories International (CRL) Financials

Annual Income Statements for Charles River Laboratories International

Quarterly Income Statements for Charles River Laboratories International

Annual Cash Flow Statements for Charles River Laboratories International

Quarterly Cash Flow Statements for Charles River Laboratories International

Annual Balance Sheets for Charles River Laboratories International

Quarterly Balance Sheets for Charles River Laboratories International

Annual Metrics And Ratios for Charles River Laboratories International

Quarterly Metrics And Ratios for Charles River Laboratories International

Financials Breakdown Chart

Key Financial Trends

Charles River Laboratories International Financials - Frequently Asked Questions

When does Charles River Laboratories International's fiscal year end?

How has Charles River Laboratories International's net income changed over the last 10 years?

What is Charles River Laboratories International's operating income?

How has Charles River Laboratories International's revenue changed over the last 10 years?

How much debt does Charles River Laboratories International have?

How much cash does Charles River Laboratories International have?

How has Charles River Laboratories International's book value per share changed over the last 10 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools